Petmed Express 2025 Q4 Earnings Wider Losses and Lingering Filing Delays
Generated by AI AgentAinvest Earnings Report Digest
Tuesday, Oct 14, 2025 11:09 pm ET2min read
PETS--
Aime Summary
Aime SummaryPetmed Express (PETS) reported its fiscal 2025 Q4 earnings on October 14, 2025. The company missed expectations with declining revenue and significantly wider net losses. No earnings guidance was provided, as the company continues to work through SEC filing delays and internal reforms.
Revenue
The total revenue of Petmed ExpressPETS-- decreased by 22.0% to $46.47 million in 2025 Q4, down from $59.53 million in 2024 Q4.
Earnings/Net Income
Petmed Express's losses deepened to $0.56 per share in 2025 Q4 from a loss of $0.24 per share in 2024 Q4 (137.6% wider loss). Meanwhile, the company's net loss widened to $-11.64 million in 2025 Q4, representing a 132.1% increase from the $-5.02 million loss recorded in 2024 Q4. The results reflect a deteriorating financial performance, with EPS indicating a significant worsening in profitability.
Price Action
The stock price of Petmed Express has climbed 3.23% during the latest trading day, has edged up 0.79% during the most recent full trading week, and has tumbled 8.57% month-to-date.
Post-Earnings Price Action Review
Board Chair and Interim CEO Leslie C. G. Campbell expressed gratitude for shareholder patience during the recent SEC filing delays and emphasized the company’s focus on operational execution and long-term value creation. He highlighted the completion of the Form 10-K filing and internal process improvements as enablers for renewed operational focus. The CEO reiterated the company’s commitment to delivering trusted pet care services and positioned the business as a 30-year digital pharmacy industry pioneer. His tone was forward-looking and optimistic, with a focus on returning to normal quarterly reporting and resuming earnings calls once SEC filings are current.
CEO Commentary
Board Chair and Interim CEO Leslie C. G. Campbell expressed gratitude for shareholder patience during the recent SEC filing delays and emphasized the company’s focus on operational execution and long-term value creation. He highlighted the completion of the Form 10-K filing and internal process improvements as enablers for renewed operational focus. The CEO reiterated the company’s commitment to delivering trusted pet care services and positioned the business as a 30-year digital pharmacy industry pioneer. His tone was forward-looking and optimistic, with a focus on returning to normal quarterly reporting and resuming earnings calls once SEC filings are current.
Guidance
The company expects to file its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025, and September 30, 2025, as soon as practicable, followed by the corresponding earnings results and announcements. While exact dates for these filings and related earnings calls remain undetermined, the company anticipates resuming its normal quarterly reporting cadence promptly once filings are current. No specific financial guidance is provided for future periods beyond the resumption of reporting.
Additional News
PetMed Express is under investigation by national shareholder rights firm Hagens Berman, which is examining whether the company intentionally misled investors about its financial reporting. The firm highlighted a series of disclosures beginning on June 16, 2025, when PetMed announced delays in filing its annual report. This led to an internal audit triggered by a whistleblower complaint about improper revenue recognition related to autoship orders and a $50 coupon campaign. The investigation intensified after the abrupt departure of the Audit Committee chair and the resignations of the CEO and CFO. On October 7, 2025, the company admitted to overstating net sales by $6.969 million and $9.01 million for the years ended March 31, 2024 and 2023, respectively, and admitted to improper timing of product shipments. As of October 9, 2025, the company had not filed its annual or most recent quarterly reports. Hagens Berman is seeking information from investors and whistleblowers who may have insights into the firm’s accounting practices.
Revenue
The total revenue of Petmed ExpressPETS-- decreased by 22.0% to $46.47 million in 2025 Q4, down from $59.53 million in 2024 Q4.
Earnings/Net Income
Petmed Express's losses deepened to $0.56 per share in 2025 Q4 from a loss of $0.24 per share in 2024 Q4 (137.6% wider loss). Meanwhile, the company's net loss widened to $-11.64 million in 2025 Q4, representing a 132.1% increase from the $-5.02 million loss recorded in 2024 Q4. The results reflect a deteriorating financial performance, with EPS indicating a significant worsening in profitability.
Price Action
The stock price of Petmed Express has climbed 3.23% during the latest trading day, has edged up 0.79% during the most recent full trading week, and has tumbled 8.57% month-to-date.
Post-Earnings Price Action Review
Board Chair and Interim CEO Leslie C. G. Campbell expressed gratitude for shareholder patience during the recent SEC filing delays and emphasized the company’s focus on operational execution and long-term value creation. He highlighted the completion of the Form 10-K filing and internal process improvements as enablers for renewed operational focus. The CEO reiterated the company’s commitment to delivering trusted pet care services and positioned the business as a 30-year digital pharmacy industry pioneer. His tone was forward-looking and optimistic, with a focus on returning to normal quarterly reporting and resuming earnings calls once SEC filings are current.
CEO Commentary
Board Chair and Interim CEO Leslie C. G. Campbell expressed gratitude for shareholder patience during the recent SEC filing delays and emphasized the company’s focus on operational execution and long-term value creation. He highlighted the completion of the Form 10-K filing and internal process improvements as enablers for renewed operational focus. The CEO reiterated the company’s commitment to delivering trusted pet care services and positioned the business as a 30-year digital pharmacy industry pioneer. His tone was forward-looking and optimistic, with a focus on returning to normal quarterly reporting and resuming earnings calls once SEC filings are current.
Guidance
The company expects to file its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025, and September 30, 2025, as soon as practicable, followed by the corresponding earnings results and announcements. While exact dates for these filings and related earnings calls remain undetermined, the company anticipates resuming its normal quarterly reporting cadence promptly once filings are current. No specific financial guidance is provided for future periods beyond the resumption of reporting.
Additional News
PetMed Express is under investigation by national shareholder rights firm Hagens Berman, which is examining whether the company intentionally misled investors about its financial reporting. The firm highlighted a series of disclosures beginning on June 16, 2025, when PetMed announced delays in filing its annual report. This led to an internal audit triggered by a whistleblower complaint about improper revenue recognition related to autoship orders and a $50 coupon campaign. The investigation intensified after the abrupt departure of the Audit Committee chair and the resignations of the CEO and CFO. On October 7, 2025, the company admitted to overstating net sales by $6.969 million and $9.01 million for the years ended March 31, 2024 and 2023, respectively, and admitted to improper timing of product shipments. As of October 9, 2025, the company had not filed its annual or most recent quarterly reports. Hagens Berman is seeking information from investors and whistleblowers who may have insights into the firm’s accounting practices.
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet